BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27852851)

  • 1. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.
    Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.
    Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells.
    Richard J; Nguyen DN; Tolbert WD; Gasser R; Ding S; Vézina D; Yu Gong S; Prévost J; Gendron-Lepage G; Medjahed H; Gottumukkala S; Finzi A; Pazgier M
    mBio; 2021 Oct; 12(5):e0140521. PubMed ID: 34579568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.
    Phad GE; Vázquez Bernat N; Feng Y; Ingale J; Martinez Murillo PA; O'Dell S; Li Y; Mascola JR; Sundling C; Wyatt RT; Karlsson Hedestam GB
    J Immunol; 2015 Jun; 194(12):5903-14. PubMed ID: 25964491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.
    Guan Y; Pazgier M; Sajadi MM; Kamin-Lewis R; Al-Darmarki S; Flinko R; Lovo E; Wu X; Robinson JE; Seaman MS; Fouts TR; Gallo RC; DeVico AL; Lewis GK
    Proc Natl Acad Sci U S A; 2013 Jan; 110(1):E69-78. PubMed ID: 23237851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1.
    Klug G; Cole FM; Hicar MD; Watt C; Peters T; Pincus SH
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete partitioning of HIV-1 Env forms revealed by viral capture.
    Stieh DJ; King DF; Klein K; Aldon Y; McKay PF; Shattock RJ
    Retrovirology; 2015 Sep; 12():81. PubMed ID: 26399966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
    Williams KL; Stumpf M; Naiman NE; Ding S; Garrett M; Gobillot T; Vézina D; Dusenbury K; Ramadoss NS; Basom R; Kim PS; Finzi A; Overbaugh J
    PLoS Pathog; 2019 Feb; 15(2):e1007572. PubMed ID: 30779811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
    J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.